• About
    • ICNMD 2022 Photos
    • ICNMD2026 Call For Proposals
    • Call For Volunteers
    • About ICNMD
    • ICNMD 2022 Committees
    • Related Events & Partners
    • Past Congresses
    • Contact
  • Venue
    • About Brussels
    • About Meeting Venue
  • Registration & Accommodation
    • Health & Safety Measures
    • Social Events
    • Registration
    • Remote Viewing Pass
    • Accommodation
  • Program
    • Full Program
    • CME Accreditation
    • Teaching & Hands-on Courses
    • Speakers and Working Groups
    • Speaker Resources
    • Patient’s Day
    • Call for Abstracts
  • Sponsorship & Exhibits
    • Sponsorship & Exhibit Opportunities
    • Confirmed Sponsors 2022
    • Confirmed Exhibitors 2022
    • Industry-Supported Symposia 2022
    • ICNMDigital Program
    • ICNMDigital Industry-Supported Symposia
    • View ICNMD 2021 Recordings
    • ICNMD 2021 Program at a Glance
    • ICNMD 2021 Abstracts
    • ICNMD 2021 Industry-Supported Symposia
    • ICNMD 2021 Product Theatre
    • ICNMD 2022 Photos
    • ICNMD2026 Call For Proposals
    • Call For Volunteers
    • About ICNMD
    • About Brussels
    • About Meeting Venue
    • ICNMD 2022 Committees
    • Related Events & Partners
    • Past Congresses
    • Contact
    • Full Program
    • CME Accreditation
    • Teaching & Hands-on Courses
    • Speakers and Working Groups
    • Speaker Resources
    • Patient’s Day
    • Call for Abstracts
    • Health & Safety Measures
    • Social Events
    • Registration
    • Remote Viewing Pass
    • Accommodation
    • Sponsorship & Exhibits Opportunities
    • Confirmed Sponsors 2022
    • Confirmed Exhibitors 2022
    • Industry-Supported Symposia 2022
    • About Brussels
    • About Meeting Venue
  • About
    • ICNMD 2022 Photos
    • ICNMD2026 Call For Proposals
    • Call For Volunteers
    • About ICNMD
    • ICNMD 2022 Committees
    • Related Events & Partners
    • Past Congresses
    • Contact
  • Venue
    • About Brussels
    • About Meeting Venue
  • Registration & Accommodation
    • Health & Safety Measures
    • Social Events
    • Registration
    • Remote Viewing Pass
    • Accommodation
  • Program
    • Full Program
    • CME Accreditation
    • Teaching & Hands-on Courses
    • Speakers and Working Groups
    • Speaker Resources
    • Patient's Day
    • Call for Abstracts
  • Sponsorship & Exhibits
    • Sponsorship & Exhibit Opportunities
    • Confirmed Sponsors 2022
    • Confirmed Exhibitors 2022
    • Industry-Supported Symposia 2022
Get Tickets!

ICNMDigital Program

[widget id="nav_menu-9"][widget id="text-8"][widget id="custom_html-3"]

11 September
12 September
13 September
14 September

09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
MUSCLE DISEASES
MUSCLE DISEASES
Scientific Session 01 (10:00 CEST / 04:00 EDT / 01:00 PDT)
10:00 - 11:00

Session Chair: Prof Marianne De Visser, The Netherlands

Inflammatory Autoimmune Myopathies
Prof Olivier Benveniste, France
30 Minutes

Genetic Therapies
Dr Kevin Flanigan, United States
30 minutes

Scientific Session 02 (11:30 CEST / 05:30 EDT / 02:30 PDT)
11:30 - 12:30

Session Chair: Prof Bjarne Udd, Finland

MYO-SEQ, Diagnosing Patients with LGMD
Prof Volker Straub, UK
30 minutes

Metabolic Therapies
Prof John Vissing, Denmark
30 minutes

Industry Supported Symposium 01 (13:00 CEST / 07:00 EDT / 04:00 PDT)
13:00 - 14:00

Sponsored Symposium
60 minutes

Scientific Session 03 (14:30 CEST / 08:30 EDT / 05:30 PDT)
14:30 - 15:30

Session Chair: Prof Antonio Tascano, Italy

Novel Image Analysis to Assess Molecular Functionality of Dystrophin in Duchenne Muscular Dystrophy Clinical Trials
Mr Dominic Scaglioni, UK
20 minutes

A Dominant PYGM Mutation Causes a New Class of Glycogen Storage Diseases
Dr Jocelyn Laporte, France
20 minutes

Therapeutic potential of antagomiR-23b for treating Myotonic Dystrophy
Sra Beatriz Llamusi, Spain
20 minutes

Industry Supported Symposium 02 (16:00 CEST / 10:00 EDT / 07:00 PDT)
16:00 - 17:00

Sponsored Symposium
60 minutes

MUSCLE DISEASES
  • Scientific Session 01 (10:00 CEST / 04:00 EDT / 01:00 PDT)
    - Inflammatory Autoimmune Myopathies
    - Genetic Therapies
    10:00 - 11:00
  • Scientific Session 02 (11:30 CEST / 05:30 EDT / 02:30 PDT)
    - MYO-SEQ, Diagnosing Patients with LGMD
    - Metabolic Therapies
    11:30 - 12:30
  • Industry Supported Symposium 01 (13:00 CEST / 07:00 EDT / 04:00 PDT)
    13:00 - 14:00
  • Scientific Session 03 (14:30 CEST / 08:30 EDT / 05:30 PDT)
    - Novel Image Analysis to Assess Molecular Functionality of Dystrophin in Duchenne Muscular Dystrophy Clinical Trials
    - A Dominant PYGM Mutation Causes a New Class of Glycogen Storage Diseases
    - Therapeutic potential of antagomiR-23b for treating Myotonic Dystrophy
    14:30 - 15:30
  • Industry Supported Symposium 02 (16:00 CEST / 10:00 EDT / 07:00 PDT)
    16:00 - 17:00

09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
PERIPHERAL NEUROPATHIES
PERIPHERAL NEUROPATHIES
Scientific Session 04 (10:00 CEST / 04:00 EDT / 01:00 PDT)
10:00 - 11:00

Session Chair: Prof Peter Van Den Bergh, Belgium

Dysimmune Nodo-Paranodopathies
Dr Luis Querol, Spain
30 minutes

Painful Channelopathies
Prof Giuseppe Lauria, Italy
30 minutes

Scientific Session 05 (11:30 CEST / 05:30 EDT / 02:30 PDT)
11:30 - 12:30

Session Chair: Dr Davide Pareyson, Italy

Charcot-Marie-Tooth and Related Neuropathies
Prof Mary Reilly, UK
30 minutes

Diabetic Neuropathy: Treatment and Costs
Dr Brian Callaghan, USA
30 minutes

Industry Supported Symposium 03 (13:00 CEST / 07:00 EDT / 04:00 PDT)
13:00 - 14:00

Sponsored Symposium
60 minutes

Scientific Session 06 (14:30 CEST / 08:30 EDT / 05:30 PDT)
14:30 - 15:30

Sessions Chair: Prof John England, USA

Combination of RNA-Interference and Gene Therapy to Treat Charcot-Marie-Tooth Type 2A
Dr Elena Abati, Italy
20 minutes

PDXK-Related Peripheral Neuropathy With Optic Atrophy. A New Treatable Disease
Dr Viorica Chelban, United Kingdom
20 minutes

De Novo Variants in POLR3B Cause Demyelinating Neuropathy, Ataxia, and Spasticity
Dr Djurdja Djordjevic, Canada
20 minutes

Industry Supported Symposium 04 (16:00 CEST / 10:00 EDT / 07:00 PDT)
16:00 - 17:00

Sponsored Symposium
60 minutes

PERIPHERAL NEUROPATHIES
  • Scientific Session 04 (10:00 CEST / 04:00 EDT / 01:00 PDT)
    - Dysimmune Nodo-Paranodopathies
    - Painful Channelopathies
    10:00 - 11:00
  • Scientific Session 05 (11:30 CEST / 05:30 EDT / 02:30 PDT)
    - Charcot-Marie-Tooth and Related Neuropathies
    - Diabetic Neuropathy: Treatment and Costs
    11:30 - 12:30
  • Industry Supported Symposium 03 (13:00 CEST / 07:00 EDT / 04:00 PDT)
    13:00 - 14:00
  • Scientific Session 06 (14:30 CEST / 08:30 EDT / 05:30 PDT)
    - Combination of RNA-Interference and Gene Therapy to Treat Charcot
    - Marie-Tooth Type 2A
    - PDXK-Related Peripheral Neuropathy With Optic Atrophy. A New Treatable Disease
    -De Novo Variants in POLR3B Cause Demyelinating Neuropathy, Ataxia, and Spasticity
    14:30 - 15:30
  • Industry Supported Symposium 04 (16:00 CEST / 10:00 EDT / 07:00 PDT)
    16:00 - 17:00

09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
NEUROMUSCULAR JUNCTION DISORDERS
NEUROMUSCULAR JUNCTION DISORDERS
Scientific Session 07 (10:00 CEST / 04:00 EDT / 01:00 PDT)
10:00 - 11:00

Session Chair: Prof Zohar Argov, Israel

Congenital Myasthenic Syndromes
Prof David Beeson, United Kingdom
30 minutes

Thymectomy
Dr Gil Wolfe, United States
30 minutes

Scientific Session 08 (11:30 CEST / 05:30 EDT / 02:30 PDT)
11:30 - 12:30

Session Chair: Prof Angela Vincent, UK

Immunoactive Drug Therapy
Prof Nils Erik Gilhus, Norway
30 minutes

Drugs Related Exacerbation
Amelia Evoli, Italy
30 minutes

Industry Supported Symposium 05 (13:00 CEST / 07:00 EDT / 04:00 PDT)
13:00 - 14:00

Sponsored Symposium
60 minutes

Scientific Session 09 (14:30 CEST / 08:30 EDT / 05:30 PDT)
14:30 - 15:30

Session Chair: Prof Susana Quijano-Roy, France

Clinical Characteristics and Outcomes of Thymoma Associated Myasthenia Gravis
Mr Rodrigo Alvarez Velasco, Spain
20 minutes

Treatment Impact on Specific Symptom MG-ADL Domains Myasthenia Gravis Patients: Phase 2 Efgartigimod Study Analysis
Dr James Howard, United States
20 minutes

Prevalence and Associated Factors of Fatigue in the Dutch MG Population
Dr Martijn Tannemaat, Netherlands
20 minutes

Industry Supported Symposium 06 (16:00 CEST / 10:00 EDT / 07:00 PDT)
16:00 - 17:00

Sponsored Symposium
60 minutes

NEUROMUSCULAR JUNCTION DISORDERS
  • Scientific Session 07 (10:00 CEST / 04:00 EDT / 01:00 PDT)
    - Congenital Myasthenic Syndromes
    - Thymectomy
    10:00 - 11:00
  • Scientific Session 08 (11:30 CEST / 05:30 EDT / 02:30 PDT)
    - Immunoactive Drug Therapy
    - Drugs Related Exacerbation
    11:30 - 12:30
  • Industry Supported Symposium 05 (13:00 CEST / 07:00 EDT / 04:00 PDT)
    13:00 - 14:00
  • Scientific Session 09 (14:30 CEST / 08:30 EDT / 05:30 PDT)
    - Clinical Characteristics and Outcomes of Thymoma Associated Myasthenia Gravis
    - Treatment Impact on Specific Symptom MG-ADL Domains Myasthenia Gravis Patients: Phase 2 Efgartigimod Study Analysis
    - Prevalence and Associated Factors of Fatigue in the Dutch MG Population
    14:30 - 15:30
  • Industry Supported Symposium 06 (16:00 CEST / 10:00 EDT / 07:00 PDT)
    16:00 - 17:00

09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
MOTOR NEURON DISEASES
MOTOR NEURON DISEASES
Scientific Session 10 (10:00 CEST / 04:00 EDT / 01:00 PDT)
10:00 - 11:00

Session Chair: Prof Marianne De Visser, The Netherlands

New guidelines For the Design and Implementation of ALS Clinical Trials
Prof Leonard Van Den Berg, Netherlands
30 minutes

Advances in Genetics & Epigenetic of ALS
Dr Bryan Traynor, United States
30 minutes

Scientific Session 11 (11:30 CEST/ 05:30 EDT / 02:30 PDT)
11:30 - 12:30

Session Chair: Prof Benedikt Schoser, Germany

Therapeutic Considerations in SMA 2020: Who, When and How to Treat
Dr Richard Finkel, United States
30 minutes

Newborn Screening
Prof Laurent Servais, UK
30 minutes

Industry Supported Symposium 07 (13:00 CEST / 07:00 EDT / 04:00 PDT)
13:00 - 14:00

Sponsored Symposium
60 minutes

Scientific Session 12 (14:30 CEST / 08:30 EDT / 05:30 PDT)
14:30 - 15:30

Session Chair: Prof Enrico Bertini, Italy

A Longitudinal Natural History Study for Type 2 and 3 Spinal Muscle Atrophy
Ms Jesica Maria Exposito Escudero, Spain
20 minutes

Cervical Spinal Cord Atrophy: An Early Marker of Survival Time in Amyotrophic Lateral Sclerosis
Miss Virginia Reyes Garrido, Spain
20 minutes

Industry Supported Symposium 08 (16:00 CEST / 10:00 EDT / 07:00 PDT)
16:00 - 17:00

Sponsored Symposium
60 minutes

MOTOR NEURON DISEASES
  • Scientific Session 10 (10:00 CEST / 04:00 EDT / 01:00 PDT)
    - New guidelines For the Design and Implementation of ALS Clinical Trials
    - Advances in Genetics & Epigenetic of ALS
    10:00 - 11:00
  • Scientific Session 11 (11:30 CEST/ 05:30 EDT / 02:30 PDT)
    - Therapeutic Considerations in SMA 2020: Who, When and How to Treat
    - Newborn Screening
    11:30 - 12:30
  • Industry Supported Symposium 07 (13:00 CEST / 07:00 EDT / 04:00 PDT)
    13:00 - 14:00
  • Scientific Session 12 (14:30 CEST / 08:30 EDT / 05:30 PDT)
    - A Longitudinal Natural History Study for Type 2 and 3 Spinal Muscle Atrophy
    - Cervical Spinal Cord Atrophy: An Early Marker of Survival Time in Amyotrophic Lateral Sclerosis
    14:30 - 15:30
  • Industry Supported Symposium 08 (16:00 CEST / 10:00 EDT / 07:00 PDT)
    16:00 - 17:00

Click here to view disclosure information for individuals involved in the educational programming for ICNMDigital.

For the list of virtual industry-supported seminars (non-accredited), please visit the Virtual Industry-Supported Symposia page.

The ICNMDigital virtual library access is now closed.


  •  

    The ICNMD is organized on behalf of the Applied Research Group on Neuromuscular Diseases of the World Federation of Neurology.
  • Stay Connected

    Keep up to date with Congress News & Alerts.
    Sign Up

     

    #ICNMD2022

  • ICNMD 2022 Congress Secretariat
    ICS International Conference Services LTD (ICS)
    710 – 1201 West Pender Street
    Vancouver, BC, Canada V6E 2V2
    P: [+1] 604 681 2153
    E: icnmd2022@icsevents.com
    Web: icnmd.org
© 2022 International Congress on Neuromuscular Diseases